Los Angeles Capital Management
HARP

Los Angeles Capital Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Los Angeles Capital Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,548
Closed -$419K – 1523
2021
Q4 		$419K Hold
5,548
– – ﹤0.01% 1090
2021
Q3 		$438K Sell
5,548
-486
-8% -$48.9K ﹤0.01% 1118
2021
Q2 		$837K Buy
6,034
+3,647
+153% +$696K ﹤0.01% 932
2021
Q1 		$499K Buy
2,387
+597
+33% +$120K ﹤0.01% 1218
2020
Q4 		$297K Hold
1,790
– – ﹤0.01% 1375
2020
Q3 		$304K Buy
1,790
+473
+36% +$68.2K ﹤0.01% 1265
2020
Q2 		$219K Buy
+1,317
New +$205K ﹤0.01% 1379

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Los Angeles Capital Management's HARP Position: Q1 2022 in Review

Los Angeles Capital Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2022, closing a stake of 5,548 shares — an estimated $419K sold.

Los Angeles Capital Management first reported a position in HARP in Q2 2020 and held it in 7 quarters. The position peaked at $837K in Q2 2021. 79 funds tracked by Wall St. Rank hold HARP as of Q1 2022.

  • Los Angeles Capital Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 5,548 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $419K.
  • Los Angeles Capital Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • Los Angeles Capital Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $837K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Los Angeles Capital Management's 13F filing for Q1 2022, filed 6 May 2022.